Department of General Surgery, University of Health Sciences, Kanuni Sultan Suleyman Training and Research Hospital, İstanbul-Turkey.
Ulus Travma Acil Cerrahi Derg. 2021 Jan;27(1):89-94. doi: 10.14744/tjtes.2020.69804.
Laparoscopic cholecystectomy (LC) is the accepted standard treatment for acute cholecystitis (AC) in patients eligible for surgery. Percutaneous cholecystostomy (PC) can provide a permanent treatment for high-risk patients for surgery or act as a bridge for later surgical treatment. This study is an evaluation of the use of PC during the current coronavirus 2019 (COVID-19) pandemic at a single hospital.
Fifty patients with AC were admitted as of the start of the COVID-19 pandemic in Turkey through June 2020. Patients with pancreatitis, cholangitis, and/or incomplete data were excluded from the study. Data of the remaining 36 patients included in the study were recorded and a descriptive statistical analysis was performed. The patients were divided into three groups: PC (n=14), only conservative treatment with antibiotherapy (OC) (n=14), and LC (n=8). The findings were compared with a group of 70 similar patients from the pre-pandemic period.
The mean age of the pandemic period patients was 53 years (range: 26-78 years). The female/male ratio was 1.11. PC was preferred in eight (11%) patients in the same period of the previous year, whereas 14 (39%) patients underwent PC in the pandemic period. Four of the 36 pandemic patients were positive for COVID-19, including one member of the PC group. There was one (7.1%) mortality in the pandemic-period PC group due to cardiac arrest. The length of hospital stay between the groups based on the type of treatment was not statistically significant.
LC is not recommended during the pandemic period; PC can be an effective and safe alternative for the treatment of AC.
腹腔镜胆囊切除术（LC）是适合手术的急性胆囊炎（AC）患者的公认标准治疗方法。经皮胆囊造口术（PC）可为手术高危患者提供永久性治疗，或作为以后手术治疗的桥梁。本研究评估了在土耳其一家医院，在当前 2019 年冠状病毒病（COVID-19）大流行期间使用 PC 的情况。
自 COVID-19 大流行开始至 2020 年 6 月，土耳其共有 50 例 AC 患者入院。排除胰腺炎、胆管炎和/或数据不完整的患者。对纳入研究的 36 例患者的资料进行记录，并进行描述性统计分析。将患者分为三组：PC 组（n=14）、仅接受抗生素治疗的保守治疗组（OC）（n=14）和 LC 组（n=8）。将这些结果与大流行前同期的 70 例类似患者组进行比较。
大流行期间患者的平均年龄为 53 岁（范围：26-78 岁）。女性/男性比例为 1.11。在去年同期，8 名（11%）患者中首选 PC，而在大流行期间有 14 名（39%）患者选择 PC。36 名大流行患者中有 4 名（7.1%）COVID-19 检测呈阳性，其中 1 名来自 PC 组。在大流行期间 PC 组有 1 例（7.1%）因心脏骤停而死亡。根据治疗类型，各组的住院时间无统计学差异。
大流行期间不推荐进行 LC；PC 可为 AC 的治疗提供有效且安全的替代方案。
